Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Wahram Andrikyan"'
Autor:
Laura Weisbach, Anna K. Schuster, Michael Hartmann, Pauline Dürr, Melanie I. Then, Wahram Andrikyan, Martin F. Fromm, Renke Maas, Katrin Farker
Publikováno v:
British Journal of Clinical Pharmacology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dfc67986c0ef3fc9e5fd67fb1ae0a20b
https://doi.org/10.1111/bcp.15730
https://doi.org/10.1111/bcp.15730
Autor:
Wahram Andrikyan, Lea Jung-Poppe, Anna Altenbuchner, Hagen Fabian Nicolaus, Barbara Pfistermeister, Harald Dormann, Martin F. Fromm, Renke Maas
Publikováno v:
Journal of Clinical Medicine; Volume 12; Issue 1; Pages: 315
Drug-related problems (DRPs), i.e., adverse drug reactions (ADRs) and medication errors (MEs), constitute a serious threat to the patient’s safety. DRPs are often insufficiently captured by clinical routine documentation, and thus, they frequently
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bceb6cb65543628690480713077e0702
https://pubmed.ncbi.nlm.nih.gov/36615115
https://pubmed.ncbi.nlm.nih.gov/36615115
Autor:
Wahram Andrikyan, Anna Maria Boehmer, Laura Weisbach, Torsten Thalheim, Anna Kathrin Schuster, Julia Palm, Petra Thürmann
Publikováno v:
Prävention und Gesundheitsförderung.
Zusammenfassung Hintergrund Mit der zunehmenden Anzahl eingenommener Arzneimittel steigt die Prävalenz von Medikationsrisiken. Hierzu zählen beispielsweise Arzneimittelwechselwirkungen, welche erwünschte und unerwünschte Wirkungen einzelner Arzne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46fe163efde54833c7a16a1ebdfd9e67
https://doi.org/10.1007/s11553-022-00976-8
https://doi.org/10.1007/s11553-022-00976-8
Publikováno v:
British Journal of Clinical Pharmacology. 88:226-236
Aims A substantial number of Summaries of Product Characteristics (SmPCs)/Prescribing Information (PI) have warnings or contraindications on QT interval prolongation. The goal of this work was to quantify usage of QT interval prolonging drugs accordi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::565ad42671fb2881d8db350e82ce2484
https://doi.org/10.1111/bcp.14951
https://doi.org/10.1111/bcp.14951
Autor:
Wahram Andrikyan, Melanie I. Then, Karl‐Günter Gaßmann, Thomas Tümena, Pauline Dürr, Martin F. Fromm, Renke Maas
Publikováno v:
British journal of clinical pharmacologyREFERENCES. 88(12)
Aims Automated checks for medication‐related problems have become a cornerstone of medication safety. In many clinical settings medication checks remain confined to drug–drug interactions because only medication data are available in an adequatel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7433be72fc8f72d7a2243b5f82b9863d
https://pubmed.ncbi.nlm.nih.gov/35877931
https://pubmed.ncbi.nlm.nih.gov/35877931
Publikováno v:
British journal of clinical pharmacologyREFERENCES. 88(1)
A substantial number of Summaries of Product Characteristics (SmPCs)/Prescribing Information (PI) have warnings or contraindications on QT interval prolongation. The goal of this work was to quantify usage of QT interval prolonging drugs according to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e3d0ad6a070b0cd6c08770cd03919141
https://pubmed.ncbi.nlm.nih.gov/34156728
https://pubmed.ncbi.nlm.nih.gov/34156728